UHPLC analysis of challenging MAbs

Article

Sponsored Content - EU

This application note using YMC-Triart Bio C4 shows a robust separation at high temperatures of 3 commercially available MAbs: Ofatumumab, Palivizumab, and Panitumumab.

Related Content